Latest News

VBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SEC

VBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

SEC Filing Details

Document Details

Form

UPLOAD

Filing Date

May 23, 2014

Document Date

May 23, 2014

Form Description

UPLOAD

Filing Group

Other

Company

VBL Therapeutics

Issuer

Vascular Biogenics Ltd.

Filing Formats

Download PDF

Investor Tools

Print Page
RSS
Email Alerts
Contact Us

About Us

Our Technology

Investor Relations

VBL Therapeutics (Nasdaq: VBLT) is developing targeted therapies for immune-inflammatory diseases. VBL’s lead immunology product candidate VB-601 is a targeted antibody for immune-inflammatory applications expected to enter Phase 1 this year that has shown disease-modifying activity across multiple preclinical models including multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease.

Latest News

VBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SEC

VBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update